
Aprea Therapeutics APRE
$ 0.73
2.63%
Annual report 2025
added 03-16-2026
Aprea Therapeutics General and Administrative Expenses 2011-2026 | APRE
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Aprea Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.48 M | 6.46 M | 8.43 M | 21 M | 13.6 M | 14.9 M | 8.59 M | 2.29 M | 2.46 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21 M | 2.29 M | 9.35 M |
Quarterly General and Administrative Expenses Aprea Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.48 M | 1.59 M | 1.76 M | - | 1.61 M | 1.85 M | 1.93 M | - | 1.72 M | 1.7 M | 3.37 M | - | 3.08 M | 15.6 M | 3.99 M | - | 3.41 M | 3.34 M | 3.43 M | - | 3.47 M | 3.79 M | 2.78 M | - | 2.31 M | 1.62 M | 729 K | - | 624 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.6 M | 624 K | 2.96 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ADC Therapeutics SA
ADCT
|
71.5 M | $ 3.78 | - | $ 105 M | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Akebia Therapeutics
AKBA
|
107 M | $ 1.35 | -2.17 % | $ 347 M | ||
|
Akari Therapeutics, Plc
AKTX
|
9.28 M | $ 3.5 | -21.7 % | $ 236 B | ||
|
Aldeyra Therapeutics
ALDX
|
9.6 M | $ 1.58 | -4.82 % | $ 94.9 M | ||
|
Aligos Therapeutics
ALGS
|
20.7 M | $ 8.36 | 4.89 % | $ 82.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.21 B | $ 330.71 | 3.72 % | $ 43.3 B | ||
|
Altimmune
ALT
|
28.1 M | $ 3.47 | 3.89 % | $ 306 M | ||
|
ALX Oncology Holdings
ALXO
|
23.8 M | $ 1.98 | 0.25 % | $ 106 M | ||
|
Amgen
AMGN
|
7.05 B | $ 346.45 | -0.43 % | $ 186 B | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Amneal Pharmaceuticals
AMRX
|
527 M | $ 12.37 | -0.92 % | $ 3.88 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Anika Therapeutics
ANIK
|
95.8 M | $ 15.0 | 1.32 % | $ 220 M | ||
|
ANI Pharmaceuticals
ANIP
|
250 M | $ 76.34 | 2.87 % | $ 1.47 B | ||
|
Annexon
ANNX
|
31.7 M | $ 5.64 | 2.45 % | $ 875 M | ||
|
Aptorum Group Limited
APM
|
5.41 M | $ 0.92 | -1.11 % | $ 5.02 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.15 | 0.48 % | $ 444 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
46.1 M | $ 8.43 | 4.98 % | $ 231 M | ||
|
Ardelyx
ARDX
|
337 M | $ 6.08 | 2.27 % | $ 1.47 B | ||
|
argenx SE
ARGX
|
308 M | $ 752.05 | 0.75 % | $ 25 B | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
Arcutis Biotherapeutics
ARQT
|
275 M | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
95.9 M | $ 11.11 | 2.4 % | $ 788 M | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
124 M | $ 61.57 | 0.88 % | $ 8.24 B | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
Assembly Biosciences
ASMB
|
19.6 M | $ 30.01 | 3.43 % | $ 336 M | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Actinium Pharmaceuticals
ATNM
|
15.2 M | $ 1.14 | 16.28 % | $ 35.6 M | ||
|
Atossa Therapeutics
ATOS
|
16 M | $ 5.21 | -2.89 % | $ 44.9 M | ||
|
Atara Biotherapeutics
ATRA
|
26.3 M | $ 5.03 | 0.7 % | $ 63.1 M | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
102 M | $ 16.04 | 2.75 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
132 M | $ 1.42 | 0.35 % | $ 378 M | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
10.9 M | - | 10.36 % | $ 9.8 M |